Rheumatologists Continue to Prefer Enbrel and Humira as Both Their First and Second Line Biologic Agents and the Combined Formulations of Orencia as the Dominant Third Line Agent
Save yourself the money and don’t buy the report!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”